L2 Consulting works with an international client base of life science industries in finance, business planning, M+A, program design, executional oversight and interim management. Scientifically, L2 has contributed to over 300 new drug clinical trial applications (preclinical), has raised over U$200m in new funding and has been pivotal in closing 6 mid-sized M&A’s in the industry (including execution of full due diligence) with deal values of up to US$50m.
As an Associate Partner in L2 Consulting, Thomas Studebaker, BS, MBA, has over 25 years of experience in successful business development for HTI Bio-Services, LAB, MPI Research and Experimur. Co-founder of Novatrix, Quivive, Oncternal Therapeutics and VelosBio (acquired by Merck for $2.75B in 2020). Active entrepreneur, investor and fund-raiser for Biopharmaceutical startup ventures. Chairman over two decades for the San Diego Biotechnology Discussion Group and Women of Bioscience.